International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord involvement but more restricted or more extensive CNS involvement may occur. The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and electronic surveys to facilitate consensus. The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG). The core clinical characteristics required for…

• G
  GlaxoSmithKline
• S
  Sanofi
• B
  Biogen
• V
  Viropharma
• TP
  Teva Pharmaceutical Industries
• AP
  Alexion Pharmaceuticals
• GC
  Guthy-Jackson Charitable Foundation
• EC
  European Committee for Treatment and Research in Multiple Sclerosis
• AT
  Acorda Therapeutics
• MS
  Multiple Sclerosis Society of Canada
• E
  Eisai
• MO
  Ministry of Education, Science and Technology
• AP
  Astellas Pharma
• TP
  Teijin Pharma
• MT
  Mitsubishi Tanabe Pharma Corporation
• OP
  Ono Pharmaceutical
• NI
  National Institutes of Health
• NP
  Novartis Pharma
• CP
  Chugai Pharmaceutical
• DS
  Daiichi Sankyo Europe